Court of Justice 25 March 2021, Case C-614/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Merck KGaA v European Commission, Generics (UK) Ltd (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressant medicines (citalopram) — Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)
Also known as
European Union · · · 31-05-2021
31.5.2021 EN Official Journal of the European Union C 206/5 Judgment of the Court (Fourth Chamber) of 25 March 2021 — Merck KGaA v European Commission, Generics (UK) Ltd (Case C-614/16 P) (1) (Appeal - Competition - Agreements, decisions and concerted practices - Pharmaceutical products - Market for antidepressant medicines (citalopram) - Settlement agreements concerning process patents concluded
Read the full text
This document is published by eur-lex.europa.eu.
Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.
Sign in to Moonlit